Abstract
Albumin is the most abundant protein in the circulation. Its main physiologic function is to maintain colloid osmotic pressure. Better understanding of albumin's other physiologic functions has expanded its application beyond maintenance of intravascular volume. In patients with cirrhosis, albumin has been used as an adjunct to diuretics to improve the diuretic response. It has also been used to prevent circulatory dysfunction developing after large-volume paracentesis. Newer indications in cirrhotic patients include preventing hepatorenal syndrome in those with spontaneous bacterial peritonitis, and treating established hepatorenal syndrome in conjunction with vasoconstrictor therapies. The use of albumin for many of these indications is controversial, mostly because of the paucity of well-designed, randomized, controlled trials. The cost of albumin infusions, lack of clear-cut benefits for survival, and fear of transmitting unknown viruses add to the controversy. The latest indication for albumin use in cirrhotic patients is extracorporeal albumin dialysis, which has shown promise for the treatment of hepatic encephalopathy; its role in hepatorenal syndrome or acute on chronic liver failure has not been established. Efforts should be made to define the indications for albumin use, dose of albumin required and predictors of response, so that patients gain the maximum benefit from its administration.
Key Points
-
Albumin is the most abundant protein in human serum. Its major function is to exert osmotic pressure, but it also has ligand binding, antioxidant and endothelial stabilizing properties
-
The use of albumin in patients with cirrhosis is controversial; there is evidence to support its use in the management of complications of cirrhosis, but there are also arguments against its use in cirrhosis, especially since albumin infusions are costly and survival has not been shown to be improved with this treatment
-
Albumin could provide some benefit in reducing the development of postparacentesis circulatory dysfunction, and in reducing the development of renal failure in selected patients with spontaneous bacterial peritonitis
-
In patients with hepatorenal syndrome, the use of albumin in conjunction with vasoconstrictor therapy is common, but albumin has not been shown to provide additional benefit
-
The molecular adsorbent recirculating system has not yet been proven to be a successful treatment for hepatorenal syndrome
-
Future efforts should concentrate on establishing when, how much, and for what indications albumin should be used
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Evans TW (2002) Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 16 (Suppl 5): 6–11
Halliwell B (1988) Albumin, an important extracellular antioxidant. Biochem Pharmacol 37: 569–571
Beeken WL et al. (1962) Studies of 131I-albumin catabolism and distribution in normal young male adults. J Clin Invest 41: 1312–1333
Peters T Jr (1997) Serum albumin. Adv Protein Chem 45: 153–203
Arroyo V and Colmenero J (2003) Use of albumin in the management of patients with decompensated cirrhosis. An independent verdict. Dig Liver Dis 35: 668–672
Nguyen MK and Kurtz I (2006) Quantitative Interrelationship between Gibbs–Donnan equilibrium, osmolality of body fluid compartments, and plasma water sodium concentration. J Appl Physiol 100: 1293–1300
Fasano M et al. (2005) The extraordinary ligand binding properties of human serum albumin. IUBMB Life 57: 787–796
Ghuman J et al. (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353: 38–52
Scharfstein JS et al. (1994) In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest 94: 1432–1439
Greco AV et al. (2000) Subclinical hepatic encephalopathy: role of tryptophan binding to albumin and the competition with indole-3-acetic acid. J Investig Med. 48: 274–280
Kouoh F et al. (1999) Antioxidant properties of albumin: effect on oxidative metabolism of human neutrophil granulocytes. Farmaco 54: 695–699
Quinlan GJ et al. (2004) Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 32: 755–759
Kragh-Hansen U et al. (2002) Practical aspects of the ligand binding and enzymatic properties of human serum albumin. Biol Pharm Bull 25: 695–704
Quinlan GJ et al. (2005) Albumin: biochemical properties and therapeutic potentials. Hepatology 42: 1211–1219
Lang JD Jr et al. (2004) Albumin and hydroxyethyl starch modulate oxidative inflammatory injury to vascular endothelium. Anesthesiology 100: 51–58
Ramirez-Vick J and Vargas FF (1993) Albumin modulation of paracellular permeability of pig vena caval endothelium shows specificity for pig albumin. Am J Physiol Heart Circ Physiol 264: H1382–H1387
Margarson MP and Soni NC (2002) Effects of albumin supplementation on microvascular permeability in septic patients. J Appl Physiol 92: 2139–2145
Mendez CM et al. (2005) Albumin therapy in clinical practice. Nutr Clin Pract 20: 314–320
Margarson MP and Soni NC (2004) Albumin, where are we now? Curr Anaesth Crit Care 15: 61–68
Cochrane Injuries Group Albumin Reviewers (1998) Human albumin administration in critically ill patients: systematic review of randomized controlled trials. BMJ 317: 235–240
The SAFE Study Investigators (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350: 2247–2256
Laub R and Strengers P (2002) Parvoviruses and blood products. Pathol Biol 50: 339–348
Wilkes MM and Navickis RJ (2001) Patient survival after human albumin administration: a meta-analysis of randomized controlled trials. Ann Intern Med 135: 149–164
Finfer SR et al. (2004) The SAFE Study: a landmark trial of the safety of albumin in intensive care. Med J Aust 181: 237–238
Schrier RW et al. (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151–1157
Borzio M et al. (2001) Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 33: 41–48
Moore KP et al. (2003) The management of ascites–report on the consensus conference of the International Ascites Club. Hepatology 38: 258–266
Burroughs AK (2003) Is the use of albumin of value in cirrhosis? The case not so in favour, or is there an alternative? Dig Liver Dis 35: 664–667
Laffi G et al. (2003) Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. Dig Liver Dis 35: 660–663
Chalasani N et al. (2001) Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol 12: 1010–1016
Gines P et al. (1988) Randomized comparative study of therapeutic parcentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94: 1493–1502
Ginès A et al. (1996) Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111: 1002–1010
Altman C et al. (1998) Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol 10: 5–10
Planas R et al. (1990) Dextran-70 versus albumin as plasma expanders in cirrhotic patients with ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 99: 1736–1744
Salerno F et al. (1991) Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 13: 707–713
Fassio E et al. (1992) Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. J Hepatol 14: 310–316
Moreau R et al. (2006) Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid. Liver Int 26: 46–54
Garcia-Compean D et al. (2002) Treatment of cirrhotic tense ascites with dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 1: 29–35
Sola-Vera J et al. (2003) Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 37: 1147–1153
Moreau R et al. (2002) Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 50: 90–94
Ruiz-del-Arbol L et al. (1997) Paracentesis-induced circulatory dysfunction: mechanism and the effect on hepatic hemodynamics in cirrhosis. Gastroenterology 113: 579–586
Peltekian K et al. (1997) The effect of large volume paracentesis on total central blood volume, systemic and renal hemodynamics and renal sodium handling in cirrhosis. Am J Gastroenterol 92: 394–399
Vermeulen LC Jr et al. (1995) A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med 155: 373–379
Runyon BA (2004) Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. Hepatology 39: 841–856
Follo A et al. (1994) Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20: 1495–1501
Hoefs JC et al. (1982) Spontaneous bacterial peritonitis. Hepatology 2: 399–407
Sort P et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341: 403–409
Patch D and Burroughs A (1999) Intravenous albumin in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341: 1773–1774
Mogyorosi A and Schubert ML (2000) Intravenous albumin reduces mortality in patients with spontaneous bacterial peritonitis. Gastroenterology 118: 231–233
Brand RE (1999) Intravenous albumin in patients with cirrhosis and spontaneous bacterial peritonitis: is it worth the cost? Am J Gastroenterol 94: 3404
Runyon BA (1999) Albumin infusion for spontaneous bacterial peritonitis. Lancet 354: 1838–1839
Fernández J et al. (2005) Randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42: 627–634
Wong F (2005) Volume expanders for spontaneous bacterial peritonitis: are we comparing oranges with oranges? Hepatology 42: 533–535
Gines P et al. (2003) Hepatorenal syndrome. Lancet 362: 1819–1827
Moreau R et al. (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122: 923–930
Guevara M et al. (1998) Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 27: 35–41
Duvoux C et al. (2002) Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 36: 374–380
Wong F et al. (2004) The use of midodrine, octreotide and transjugular intrahepatic portosystemic stent shunt in the treatment of cirrhotic patients with ascites and renal dysfunction including hepatorenal syndrome. Hepatology 40: 55–64
Ortega R et al. (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36: 941–948
McCormick PA et al. (1990) Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut 31: 204–207
Jalan R and Kapoor D (2004) Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci 106: 467–474
Butterworth RF (2003) Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: potential for improvement following their removal by liver assist devices. Liver Int 23 (Suppl 3): 5–9.
Lumsden A et al. (1988) Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 8: 232–236
Sogni P et al. (1992) Evidence for normal nitric oxide-mediated vasodilator tone in conscious rats with cirrhosis. Hepatology 16: 980–983
Stange J et al. (2005) Short-term survival of patients with severe intractable hepatic encephalopathy: the role of albumin dialysis. [Abstract]. Hepatology 42 (Suppl 1): 286A
Mitzner SR et al. (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 6: 277–286
Stange J et al. (2002) The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 26: 103–110
Sen S et al. (2004) Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 10: 1109–1119
Cook D (2004) Is albumin safe? N Engl J Med 350: 2294–2296
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has received grant support from Gambro Inc, which is one of the companies that supply the MARS machine.
Rights and permissions
About this article
Cite this article
Wong, F. Drug Insight: the role of albumin in the management of chronic liver disease. Nat Rev Gastroenterol Hepatol 4, 43–51 (2007). https://doi.org/10.1038/ncpgasthep0680
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0680
This article is cited by
-
Lysine reactivity profiling reveals molecular insights into human serum albumin–small-molecule drug interactions
Analytical and Bioanalytical Chemistry (2021)
-
Acute kidney injury: prediction, prognostication and optimisation for liver transplant
Hepatology International (2020)
-
Acute kidney injury in children with chronic liver disease
Pediatric Nephrology (2019)
-
Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study
Digestive Diseases and Sciences (2016)
-
Albumin Gains Immune Boosting Credibility
Clinical and Translational Gastroenterology (2015)